Table 1

Comparison between CA9 expression and pimonidazole binding in cervical cancers

PatientAgeSmokerFIGOa cervical cancer stageHistology% Pimopositive area% CA9- positive area
149NoIIbSquamous13.627.7
271NoIVaSquamous6.418.3
359NoIIbAdeno314
434YesIIbSquamous5.713
546YesIIIbSquamous8.111.7
652No1b2Squamous5.711.4
759NoIIIbSquamous5.110
833Yes1b2Squamous3.67.1
947No1b1Adeno4.37
1042NoIIaAdeno3.16.9
1167No1b2Adeno4.66.2
1233YesIIbSquamous3.14.4
1343NoIIbSquamous2.34
1438No1b2Squamous1.22
1541No1b1Adeno1.12
1641No1b1Squamous1.41.8
1735Yes1b2Squamous5.11.6
1841Yes1b2Squamous1.41.6
  • a FIGO, Fédération Internationale des Gynecologistes et Obstetristes; Pimo, pimonidazole; Adeno, adenocarcinoma.